Member LoginDividend CushionValue Trap
|
Valuentum
Reports
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Jun 13, 2012
Johnson and Johnson’s Deal for Synthes Closes; Healthcare Spending Will Grow
We take a look at some recent developments in the healthcare industry. Mar 6, 2012
Merck Weighed Down by Currency But Reaffirms Full-Year 2012 Outlook
Merck said that first-quarter performance would be weighed down by currency, but the drugmaker reaffirmed its full-year 2012 results. We are maintaining our fair value estimate. Jul 21, 2011
Merck's Shares Look Undervalued
We take a look at Merck's valuation. Jul 11, 2011
Looking for a Pullback to Pick Up Johnson & Johnson's Shares
We think J&J's shares are fully-valued at this time, but we'd be looking to pick some up if the firm offered a dividend yield of 4%. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
